https://media.ideayabio.com/ https://media.ideayabio.com/2026-04-30-IDEAYA-Biosciences-to-Initiate-New-Drug-Application-Submission-from-the-Darovasertib-OptimUM-02-Trial-under-the-Oncology-Center-of-Excellence-Real-time-Oncology-Review-RTOR-Program Thu, 30 Apr 2026 06:00:00 -0400 https://media.ideayabio.com/2026-04-30-IDEAYA-Biosciences-to-Initiate-New-Drug-Application-Submission-from-the-Darovasertib-OptimUM-02-Trial-under-the-Oncology-Center-of-Excellence-Real-time-Oncology-Review-RTOR-Program https://media.ideayabio.com/2026-04-21-IDEAYA-Biosciences-Announces-Late-Breaking-Abstract-Oral-Presentation-at-ASCO-2026-to-Provide-Complete-Data-from-Phase-2-3-Registrational-Trial-OptimUM-02-of-Darovasertib-in-Combination-with-Crizotinib-in-1L-HLA-A2-Negative-Metastatic-Uveal-Mel Tue, 21 Apr 2026 10:15:00 -0400 https://media.ideayabio.com/2026-04-21-IDEAYA-Biosciences-Announces-Late-Breaking-Abstract-Oral-Presentation-at-ASCO-2026-to-Provide-Complete-Data-from-Phase-2-3-Registrational-Trial-OptimUM-02-of-Darovasertib-in-Combination-with-Crizotinib-in-1L-HLA-A2-Negative-Metastatic-Uveal-Mel https://media.ideayabio.com/2026-04-13-IDEAYA-Biosciences-and-Servier-Announce-Positive-Topline-Results-from-Phase-2-3-Registrational-Trial-OptimUM-02-of-Darovasertib-in-Combination-with-Crizotinib-in-First-line-HLA-A-02-01-Negative-Metastatic-Uveal-Melanoma Mon, 13 Apr 2026 06:00:00 -0400 https://media.ideayabio.com/2026-04-13-IDEAYA-Biosciences-and-Servier-Announce-Positive-Topline-Results-from-Phase-2-3-Registrational-Trial-OptimUM-02-of-Darovasertib-in-Combination-with-Crizotinib-in-First-line-HLA-A-02-01-Negative-Metastatic-Uveal-Melanoma https://media.ideayabio.com/2026-04-10-IDEAYA-Biosciences-to-Announce-Topline-Results-from-Phase-2-3-OptimUM-02-Trial-in-Metastatic-Uveal-Melanoma-on-Monday,-April-13,-2026 Fri, 10 Apr 2026 16:05:00 -0400 https://media.ideayabio.com/2026-04-10-IDEAYA-Biosciences-to-Announce-Topline-Results-from-Phase-2-3-OptimUM-02-Trial-in-Metastatic-Uveal-Melanoma-on-Monday,-April-13,-2026 https://media.ideayabio.com/2026-04-06-IDEAYA-Biosciences-Announces-First-Patient-In-for-Phase-1-Trial-of-IDE574,-a-Potential-First-In-Class-Dual-Inhibitor-of-KAT6-7-to-Target-Multiple-Solid-Tumor-Indications,-including-Breast,-Prostate,-CRC,-and-Lung-Cancer Mon, 06 Apr 2026 06:00:00 -0400 https://media.ideayabio.com/2026-04-06-IDEAYA-Biosciences-Announces-First-Patient-In-for-Phase-1-Trial-of-IDE574,-a-Potential-First-In-Class-Dual-Inhibitor-of-KAT6-7-to-Target-Multiple-Solid-Tumor-Indications,-including-Breast,-Prostate,-CRC,-and-Lung-Cancer